AtriCure, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
AtriCure reported Q3 2026 worldwide revenue of $154.5 million, up 15.0% YoY ($18.7M U.S. growth driven by cryoSPHERE MAX, EnCompass, and AtriClip devices; minimally invasive ablation declined). Net income swung to $4.1 million profit (vs. $0.3M loss in Q3 2025); adjusted EBITDA was $26.8 million (+51% YoY). Gross margin expanded 180 basis points to 77.3%. Full-year 2026 guidance raised to $606–610M revenue and $91–94M adjusted EBITDA.
Why this rating
Strong quarter with margin expansion and profitability inflection; 15% organic growth healthy but routine for medical-device sector. Revenue ~$154M is ~10% of $1.6B market cap—meaningful but not transformational. Guidance raise modest relative to company size.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.